

---

# Contents

## Part I

- 1 Prehypertension: Definitions, Clinical Significance and Therapeutic Approaches—To Treat or not to Treat? . . . . .** 3  
Stevo Julius and Carlos A. Feldstein
- 2 Clinical Significance and Treatment Requirements in White Coat and Masked Hypertension . . . . .** 13  
Jean-Michel Mallion
- 3 Resistant Hypertension: Epidemiological and Evolving Therapeutic Concepts . . . . .** 25  
Guido Grassi
- 4 Primary Aldosteronism: Rare or Common Condition in Hypertensive Patients and Normotensive Individuals? . . . . .** 33  
Gian Paolo Rossi, Teresa Maria Seccia and Paola Caielli
- 5 Hypertension in the Very Old: Special Features, Therapeutic Approaches, and Problems . . . . .** 45  
Athanasios Benetos, Ulrich M. Vischer and Ghassan Wafar

## Part II

- 6 Ambulatory Blood Pressure in Clinical Practice: Clinical Relevance of Circadian Rhythm and Nocturnal Dip. . . . .** 59  
Josep Redon and Fernando Martinez
- 7 Morning Surge in Blood Pressure in Hypertension: Clinical Relevance, Prognostic Significance, and Therapeutic Approach . . . . .** 71  
Kazuomi Kario

<b>8</b>	<b>Short-Term and Long-Term Blood Pressure Variability . . . . .</b>	<b>91</b>
	Giuseppe Mancia	
<b>9</b>	<b>Home Blood Pressure Monitoring in Hypertension . . . . .</b>	<b>103</b>
	Gianfranco Parati, Juan E. Ochoa and Grzegorz Bilo	
<b>10</b>	<b>Obstructive Sleep Apnea. . . . .</b>	<b>121</b>
	Jacek Wolf and Krzysztof Narkiewicz	
<b>11</b>	<b>Hypertension, Obesity, and Metabolic Syndrome. . . . .</b>	<b>133</b>
	Peter M. Nilsson	
<b>12</b>	<b>Salt, Hypertension, and Cardiovascular Disease. . . . .</b>	<b>147</b>
	Pasquale Strazzullo, Ferruccio Galletti and Ivana Savino	
<b>13</b>	<b>The Optic Fundus and Retinal Circulation: New Technology for an Old Examination . . . . .</b>	<b>157</b>
	Martin Ritt and Roland E. Schmieder	
 <b>Part III</b>		
<b>14</b>	<b>Arterial Stiffness as an Early Marker of Organ Damage . . . . .</b>	<b>171</b>
	Stephane Laurent and Pierre Boutouyrie	
<b>15</b>	<b>Central Aortic Pressure: The Next Frontier in Blood Pressure Measurement? . . . . .</b>	<b>181</b>
	Bryan Williams and Peter S. Lacy	
<b>16</b>	<b>Assessment of Total Cardiovascular Risk in Hypertension: The Role of Subclinical Organ Damage. . . . .</b>	<b>199</b>
	Renata Cífková	
<b>17</b>	<b>The Microcirculation and Hypertension . . . . .</b>	<b>213</b>
	H. A. J. Struijker-Boudier and Bart F. J. Heijnen	
<b>18</b>	<b>Smoking, Nicotine and Blood Pressure . . . . .</b>	<b>225</b>
	Dagmara Hering and Krzysztof Narkiewicz	
<b>19</b>	<b>Biomarkers in Hypertension . . . . .</b>	<b>237</b>
	Rhian M. Touyz and Dylan Burger	

**Part IV**

<b>20</b>	<b>Antihypertensive Therapy Benefits: Pleiotropic Versus Blood Pressure-Dependent Mechanisms. . . . .</b>	<b>249</b>
	Sverre E. Kjeldsen and Gordon T. McInnes	
<b>21</b>	<b>Blood Pressure Targets with Antihypertensive Treatment . . . . .</b>	<b>267</b>
	Giuseppe Mancia	
<b>22</b>	<b>The Role of the Polypill in Hypertension. . . . .</b>	<b>279</b>
	Andrew Mente, Prem Pais, Denis Xavier, Koon Teo and Salim Yusuf	
<b>23</b>	<b>J-Curve Phenomenon: Does It Exist? . . . . .</b>	<b>295</b>
	Sripal Bangalore and Franz H. Messerli	
<b>24</b>	<b>Residual Risk in Treated Hypertension . . . . .</b>	<b>309</b>
	Alberto Zanchetti	
<b>25</b>	<b>Poor BP Control in the Hypertensive Population: Which Factors are Involved? . . . . .</b>	<b>323</b>
	Lisheng Liu and Xin-Hua Zhang	
<b>26</b>	<b>Ramadan Fasting in Health and Disease . . . . .</b>	<b>331</b>
	Adel E. Berbari, Najla A. Daouk, Samir G. Mallat and Abdo R. Jurjus	
<b>27</b>	<b>Postmenopausal Hormone Therapy and Blood Pressure. . . . .</b>	<b>347</b>
	Zeinab Issa, Ellen W. Seely and Ghada El-Hajj Fuleihan	
<b>28</b>	<b>Treating Pain and Inflammation in Hypertension . . . . .</b>	<b>373</b>
	William B. White, Ravi Marfatia and William L. Baker	
<b>29</b>	<b>Sexual Function in Untreated and Treated Hypertension. . . . .</b>	<b>389</b>
	Margus Viigimaa and Michael Dumas	
<b>30</b>	<b>Cognitive Function and Dementia in Hypertension: Epidemiologic and Therapeutic Aspects. . . . .</b>	<b>399</b>
	Jun Hata, Hisatomi Arima, Craig S. Anderson and John Chalmers	
<b>31</b>	<b>Can Hypertension Be Prevented? . . . . .</b>	<b>413</b>
	Charlotte Jones and Norm R. C. Campbell	

<b>32</b>	<b>Atrial Fibrillation. Modern Epidemiologic and Therapeutic Aspects. . . . .</b>	<b>427</b>
	Leonidas E. Poulimenos, Manolis S. Kallistratos and Athanasios J. Manolis	
<b>33</b>	<b>Genetics and Hypertension: Which Information for Clinical Practice . . . . .</b>	<b>439</b>
	Sandosh Padmanabhan and Anna F. Dominiczak	
<b>34</b>	<b>Dual Blockade of the Renin–Angiotensin–Aldosterone System: Benefits Versus Adverse Outcomes . . . . .</b>	<b>453</b>
	Michael R. Lattanzio and Matthew R. Weir	
<b>35</b>	<b>The Long-Term Effects of RAAS Blockade on Renal Function. . .</b>	<b>467</b>
	César Cerezo and Luis Miguel Ruilope	
	<b>Index . . . . .</b>	<b>479</b>



<http://www.springer.com/978-88-470-2600-1>

Special Issues in Hypertension

Berbari, A.; Mancia, G. (Eds.)

2012, X, 486 p., Hardcover

ISBN: 978-88-470-2600-1